Review ArticleClinical Review

Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions

Leigh Perreault, Lauren Vincent, Joshua J. Neumiller and Tricia Santos-Cavaiola
The Journal of the American Board of Family Medicine May 2019, 32 (3) 431-447; DOI: https://doi.org/10.3122/jabfm.2019.03.180162

References

  1. 1.↵
    1. Rawshani A,
    2. Rawshani A,
    3. Franzén S,
    4. et al
    . Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407–18.
    OpenUrlCrossRefPubMed
  2. 2.↵
    World Health Organization (WHO). Global report on diabetes: executive summary. 2016. Available from: http://apps.who.int/iris/bitstream/10665/204874/1/WHO_NMH_NVI_16.3_eng.pdf. Accessed December 2018.
  3. 3.↵
    Centers for Disease Control and Prevention (CDC). National diabetes statistics report, 2017. Estimates of diabetes and its burden in the United States. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed December 2018.
  4. 4.↵
    1. Stratton IM,
    2. Adler AI,
    3. Neil HA,
    4. et al
    . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Holman RR,
    2. Paul SK,
    3. Bethel MA,
    4. Matthews DR,
    5. Neil HA
    . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Carls G,
    2. Huynh J,
    3. Tuttle E,
    4. Yee J,
    5. Edelman SV
    . Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther 2017;8:863–73.
    OpenUrlPubMed
  8. 8.↵
    American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care 2018;1:S1–S153.
    OpenUrl
  9. 9.↵
    1. Hirsch IB
    . Insulin analogues. N Engl J Med 2005;352:174–83.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Bolli GB,
    2. Riddle MC,
    3. Bergenstal RM,
    4. et al
    . New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386–94.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Zinman B,
    2. Philis-Tsimikas A,
    3. Cariou B,
    4. et al
    . Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464–71.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Hayes RP,
    2. Fitzgerald JT,
    3. Jacober SJ
    . Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008;62:860–8.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Beaser RS,
    2. Okeke E,
    3. Neighbours J,
    4. Brown J,
    5. Ronk K,
    6. Wolyniec WW
    . Coordinated primary and specialty care for type 2 diabetes mellitus, guidelines, and systems: an educational needs assessment. Endocr Pract 2011;17:880–90.
    OpenUrlPubMed
  14. 14.↵
    1. Philis-Tsimikas A
    . Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med 2013;126:S21–S27.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Karter AJ,
    2. Subramanian U,
    3. Saha C,
    4. et al
    . Barriers to insulin initiation: the Translating Research into Action for Diabetes Insulin Starts Project. Diabetes Care 2010;33:733–5.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Perez-Nieves M,
    2. Kabul S,
    3. Desai U,
    4. et al
    . Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin 2016;32:669–80.
    OpenUrl
  17. 17.↵
    1. Khunti K,
    2. Nikolajsen A,
    3. Thorsted BL,
    4. Andersen M,
    5. Davies MJ,
    6. Paul SK
    . Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab 2016;18:401–9.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Dalal MR,
    2. Grabner M,
    3. Bonine N,
    4. Stephenson JJ,
    5. DiGenio A,
    6. Bieszk N
    . Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract 2016;121:17–26.
    OpenUrl
  19. 19.↵
    1. Stark Casagrande S,
    2. Fradkin JE,
    3. Saydah SH,
    4. Rust KF,
    5. Cowie CC
    . The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 2013;36:2271–9.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Korytkowski M
    . When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;3:S18–S24.
    OpenUrl
  21. 21.↵
    1. Khunti K,
    2. Millar-Jones D
    . Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes 2017;11:3–12.
    OpenUrlPubMed
  22. 22.↵
    1. Peyrot M,
    2. Rubin RR,
    3. Khunti K
    . Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010;4:S11–S18.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Seaquist ER,
    2. Anderson J,
    3. Childs B,
    4. et al
    . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384–95.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Barendse S,
    2. Singh H,
    3. Frier BM,
    4. Speight J
    . The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med 2012;29:293–302.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Berard L,
    2. Bonnemaire M,
    3. Mical M,
    4. Edelman S
    . Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey. Diabetes Obes Metab 2018;20:301–8.
    OpenUrl
  26. 26.↵
    1. Bolli GB,
    2. Riddle MC,
    3. Bergenstal RM,
    4. Wardecki M,
    5. Goyeau H,
    6. Home PD
    . Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab 2017;43:351–8.
    OpenUrlPubMed
  27. 27.↵
    1. Ritzel R,
    2. Roussel R,
    3. Bolli GB,
    4. et al
    . Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17:859–67.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Russell-Jones D,
    2. Gall MA,
    3. Niemeyer M,
    4. Diamant M,
    5. Del Prato S
    . Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 2015;25:898–905.
    OpenUrl
  29. 29.↵
    1. Brunton SA,
    2. Kruger DF,
    3. Funnell MM
    . Role of emerging insulin technologies in the initiation and intensification of insulin therapy for diabetes in primary care. Clin Diabetes 2016;34:34–43.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Gupta S,
    2. Wang H,
    3. Skolnik N,
    4. et al
    . Treatment dosing patterns and clinical outcomes for patients with type 2 diabetes starting or switching to treatment with insulin glargine (300 units per milliliter) in a real-world setting: a retrospective observational study. Adv Ther 2018;35:43–55.
    OpenUrl
  31. 31.↵
    1. Davis SN,
    2. Renda SM
    . Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ 2006;32:146S–52S.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Kunt T,
    2. Snoek FJ
    . Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009;6–10.
  33. 33.↵
    1. McFarlane SI
    . Insulin therapy and type 2 diabetes: management of weight gain. J Clin Hypertens (Greenwich) 2009;11:601–7.
    OpenUrlPubMed
  34. 34.↵
    1. Haque M,
    2. Emerson SH,
    3. Dennison CR,
    4. Navsa M,
    5. Levitt NS
    . Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. S Afr Med J 2005;95:798–802.
    OpenUrlPubMedWeb of Science
  35. 35.↵
    1. Hayat AS,
    2. Shaikh N
    . Barriers and myths to initiate insulin therapy for type 2 diabetes mellitus at primary health care centers of Hyderabad district. World Applied Sci 2010;8:66–72.
    OpenUrl
  36. 36.↵
    1. Bin Rsheed A,
    2. Chenoweth I
    . Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes 2017;8:28–39.
    OpenUrl
  37. 37.↵
    1. Brod M,
    2. Kongsø JH,
    3. Lessard S,
    4. Christensen TL
    . Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res 2009;18:23–32.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Davies MJ,
    2. D'Alessio DA,
    3. Fradkin J,
    4. et al
    . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–701.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Garber AJ,
    2. Abrahamson MJ,
    3. Barzilay JI,
    4. et al
    . Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract 2018;24:91–120.
    OpenUrlPubMed
  40. 40.↵
    1. Raslová K,
    2. Bogoev M,
    3. Raz I,
    4. Leth G,
    5. Gall MA,
    6. Hâncu N
    . Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193–201.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Hermansen K,
    2. Davies M,
    3. Derezinski T,
    4. Martinez Ravn G,
    5. Clauson P,
    6. Home P
    . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269–74.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Rodbard HW,
    2. Cariou B,
    3. Zinman B,
    4. et al
    . Comparison of insulin degludec with insulin glargine in insulin-naïve subjects with type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med 2013;30:1298–304.
    OpenUrl
  43. 43.↵
    1. Cichosz SL,
    2. Lundby-Christensen L,
    3. Johansen MD,
    4. et al
    . Prediction of excessive weight gain in insulin treated patients with type 2 diabetes. J Diabetes 2017;9:325–31.
    OpenUrl
  44. 44.↵
    1. van Dieren S,
    2. Czernichow S,
    3. Chalmers J,
    4. et al
    . Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012;14:464–9.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Hirsch IB,
    2. Bergenstal RM,
    3. Parkin CG,
    4. Wright E,
    5. Buse JB
    . A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005;23:78–86.
    OpenUrlFREE Full Text
  46. 46.↵
    1. Polonsky WH,
    2. Jackson RA
    . What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes 2004;22:147–50.
    OpenUrlFREE Full Text
  47. 47.↵
    1. Peyrot M,
    2. Rubin RR,
    3. Lauritzen T,
    4. et al
    . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–9.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Nakar S,
    2. Yitzhaki G,
    3. Rosenberg R,
    4. Vinker S
    . Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007;21:220–6.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Gerstein HC,
    2. Bosch J,
    3. Dagenais GR
    ORIGIN trial investigators, Gerstein HC, Bosch J, Dagenais GR. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–28.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Gilbert RE,
    2. Mann JF
    ORIGIN trial investigators, Gilbert RE, Mann JF. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014;57:1325–31.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Marso SP,
    2. McGuire DK,
    3. Zinman B,
    4. et al
    . Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723–32.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Yoshioka N,
    2. Ishii H,
    3. Tajima N,
    4. Iwamoto Y
    . Differences in physician and patient perceptions about insulin therapy for management of type 2 diabetes: the DAWN Japan study. Curr Med Res Opin 2014;30:177–83.
    OpenUrl
  53. 53.↵
  54. 54.↵
    1. Ratanawongsa N,
    2. Crosson JC,
    3. Schillinger D,
    4. Karter AJ,
    5. Saha CK,
    6. Marrero DG
    . Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ 2012;38:94–100.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Karter AJ,
    2. Parker MM,
    3. Moffet HH,
    4. Ahmed AT,
    5. Schmittdiel JA,
    6. Selby JV
    . New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 2009;44:1640–61.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Available from: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes. Accessed December 2018.
  57. 57.↵
    1. Meneghini L,
    2. Koenen C,
    3. Weng W,
    4. Selam JL
    . The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab 2007;9:902–13.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    1. Blonde L,
    2. Merilainen M,
    3. Karwe V,
    4. Raskin P
    , TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab 2009;11:623–31.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Bajaj HS,
    2. Venn K,
    3. Ye C,
    4. Aronson R
    . Randomized trial of long-acting insulin glargine titration web tool (LTHome) versus enhanced usual therapy of glargine titration (INNOVATE Trial). Diabetes Technol Ther 2016;18:610–5.
    OpenUrl
  60. 60.↵
    1. Padhye NS,
    2. Jing W
    . Pattern of active and inactive sequences of diabetes self-monitoring in mobile phone and paper diary users. Conf Proc IEEE Eng Med Biol Soc 2015;2015:7630–3.
    OpenUrl
  61. 61.↵
    US Food and Drug Administration (FDA). My Dose Coach Section 510(k) approval. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163099.pdf. Accessed December 2018.
  62. 62.↵
    Mobihealthnews. Sanofi gets FDA clearance for insulin dose calculator app. Available from: http://www.mobihealthnews.com/content/sanofi-gets-fda-clearance-insulin-dose-calculator-app. Accessed December 2018.
  63. 63.↵
    diaTribe. FDA clears “My Dose Coach” app to optimize basal insulin dosing. Available from: https://diatribe.org/fda-clears-my-dose-coach-app-to-optimize-basal-insulin-dosing. Accessed December 2018.
  64. 64.↵
    1. Goldman J,
    2. Gill J,
    3. Horn T,
    4. Reid T,
    5. Strong J,
    6. Polonsky W
    . Improved treatment engagement among patients receiving insulin glargine 300 units/mL who enrolled and received live support through the COACH patient support program. Presented at the American Association of Clinical Endocrinologists (AACE) Annual Meeting May 3–7, 2017, Austin, TX.
  65. 65.↵
    1. Mehmet S,
    2. Hussey C,
    3. Ibrahim S
    . Patients' perceptions of injecting insulin and self-monitoring of blood glucose in the presence of others. Pract Diabetes 2015;32:59–63.
    OpenUrl
  66. 66.↵
    1. Funnell MM
    . Lessons from DAWN: implementing effective insulin therapy. The Internet Journal of Advanced Nursing Practice 2008;10:1–10.
    OpenUrl
  67. 67.↵
    1. Kruger DF,
    2. LaRue S,
    3. Estepa P
    . Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes 2015;8:49–56.
    OpenUrlPubMed
  68. 68.↵
    1. Hermanns N,
    2. Mahr M,
    3. Kulzer B,
    4. Skovlund SE,
    5. Haak T
    . Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study. Health Qual Life Outcomes 2010;8:113.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Mollema ED,
    2. Snoek FJ,
    3. Pouwer F,
    4. Heine RJ,
    5. van der Ploeg HM
    . Diabetes Fear of Injecting and Self-testing Questionnaire: a psychometric evaluation. Diabetes Care 2000;23:765–9.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Uman LS,
    2. Chambers CT,
    3. McGrath PJ,
    4. Kisely S
    . A systematic review of randomized controlled trials examining psychological interventions for needle-related procedural pain and distress in children and adolescents: an abbreviated Cochrane review. J Pediatr Psychol 2008;33:842–54.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Inzucchi SE,
    2. Bergenstal RM,
    3. Buse JB,
    4. et al
    . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9.
    OpenUrlFREE Full Text
  72. 72.↵
    1. Rosenstock J,
    2. Hollander P,
    3. Bhargava A,
    4. et al
    . Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015;17:734–41.
    OpenUrl
  73. 73.↵
    1. Blevins TC,
    2. Dahl D,
    3. Rosenstock J,
    4. et al
    . Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: The ELEMENT 1 study. Diabetes Obes Metab 2015;17:726–33.
    OpenUrl
  74. 74.↵
  75. 75.↵
    1. Bailey TS,
    2. Pettus J,
    3. Roussel R,
    4. et al
    . Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. Diabetes Metab 2018;44:15–21.
    OpenUrlPubMed
  76. 76.↵
    1. Becker RH,
    2. Dahmen R,
    3. Bergmann K,
    4. Lehmann A,
    5. Jax T,
    6. Heise T
    . New insulin glargine 300 unit. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 unit. mL-1. Diabetes Care 2015;38:637–43.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Bergenstal RM,
    2. Bailey TS,
    3. Rodbard D,
    4. et al
    . Comparison of insulin glargine 300 units/ml and 100 units/ml in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care 2017;40:554–60.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Shiramoto M,
    2. Eto T,
    3. Irie S,
    4. et al
    . Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015;17:254–60.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Gough SC,
    2. Bhargava A,
    3. Jain R,
    4. Mersebach H,
    5. Rasmussen S,
    6. Bergenstal RM
    . Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536–42.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Zhou FL,
    2. Ye F,
    3. Berhanu P,
    4. et al
    . Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes Obes Metab 2018;20:1293–7.
    OpenUrl
  81. 81.↵
    1. Blonde L,
    2. Zhou FL,
    3. Bosnyak Z,
    4. et al
    . Real-world evidence demonstrates comparable clinical outcomes of switching from insulin glargine 100 U/mL (Gla-100) to insulin glargine 300 U/mL (Gla-300) vs insulin degludec (IDeg) in patients with type 2 diabetes. Presented at the 15th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), November 30–December 2, 2017, Los Angeles, CA.
  82. 82.↵
    1. Meneghini L,
    2. Zhou FL,
    3. Bosnyak Z,
    4. Berria R,
    5. Jimenez J,
    6. Bailey TS
    . Hypoglycemia risk associated with basal insulin use in type 2 diabetes (T2DM): the LIGHTNING study. Presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD), February 14–17, 2018, Vienna, Austria.
  83. 83.↵
    1. Landstedt-Hallin L,
    2. Gundgaard J,
    3. Ericsson Å,
    4. Ellfors-Zetterlund S
    . Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin 2017;33:647–55.
    OpenUrl
  84. 84.↵
    1. Bohn B,
    2. Zimmermann A,
    3. Wagner C,
    4. et al
    . Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry. Diabetes Res Clin Pract 2017;129:52–8.
    OpenUrl
  85. 85.↵
    1. Riddle MC,
    2. Bolli GB,
    3. Home PD,
    4. et al
    . Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther 2016;18:252–7.
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Meneghini L,
    2. Atkin SL,
    3. Gough SC,
    4. et al
    . The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858–64.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    Toujeo (insulin glargine injection) U-300 for subcutaneous use. Prescribing information. Bridgewater, NJ: Sanofi-Aventis US, LLC; September 2015. Available from: http://products.sanofi.us/toujeo/toujeo.pdf. Accessed December 2018.
  88. 88.↵
    Tresiba (insulin degludec injection). Prescribing information. Plainsboro, NJ: Novo Nordisk, Inc. December 2016. Available from: http://www.novo-pi.com/tresiba.pdf. Accessed December 2018.
  89. 89.↵
    1. Heise T,
    2. Meneghini LF
    . Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract 2014;20:75–83.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Yale JF,
    2. Berard L,
    3. Groleau M,
    4. Javadi P,
    5. Stewart J,
    6. Harris SB
    . TITRATION: a randomized study to assess 2 treatment algorithms with new insulin glargine 300 units/mL. Can J Diabetes 2017;41:478–84.
    OpenUrl
  91. 91.↵
    1. Berard L,
    2. Antonishyn N,
    3. Arcudi K,
    4. et al
    . Insulin matters: a practical approach to basal insulin management in type 2 diabetes. Diabetes Ther 2018;9:501–19.
    OpenUrl
  92. 92.↵
    1. Deakin T,
    2. McShane CE,
    3. Cade JE,
    4. Williams RD
    . Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005:CD003417.
  93. 93.↵
    Tresiba® dosing and device. Available from: https://www.tresibapro.com/dosing-and-device/starting-patients.html. Accessed December 2018.
  94. 94.↵
    Toujeo® insulin dosing and titration calculator. Available from: https://www.toujeopro.com/toujeo-insulin-dosing-and-titration-calculator. Accessed December 2018.
  95. 95.↵
    Lantus® prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021081s034lbl.pdf. Accessed December 2018.
  96. 96.↵
    Levemir® prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf. Accessed December 2018.
  97. 97.↵
    Basaglar® prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205692lbl.pdf. Accessed December 2018.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords